JNK Inhibitor IX – 50 mg

Brand:
Cayman
CAS:
312917-14-9
Storage:
22
UN-No:
Non-Hazardous - /

c-Jun N-terminal kinases (JNKs) are MAP kinase family members that become highly activated after cells are exposed to stress conditions and are poorly activated by exposure to growth factors or mitogens.{17156} They have been implicated in neurodegeneration, rheumatoid arthritis, inflammation, cancer, and diabetes. JNK1 and JNK2 are widely expressed throughout the body whereas JNK3 is predominantly distributed in the brain. JNK Inhibitor IX is a thienylnaphthamide compound that targets the ATP binding site of JNK2 and JNK3, disrupting activity with pIC50 values of 6.5 and 6.7, respectively.{25564} It demonstrates little activity against JNK1, p38α, and a panel of more than 30 other kinases (pIC50 < 5.0).{25564}  

 

SKU: - Category:

Description

A thienylnaphthamide compound that selectively targets the ATP binding site of JNK2 and JNK3 (pIC50s = 6.5 and 6.7, respectively)


Formal name: N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)-1-naphthalenecarboxamide

Synonyms:  c-Jun N-terminal Kinase Inhibitor IX|TCS JNK 5a

Molecular weight: 332.4

CAS: 312917-14-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|JNK||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cell Biology|Cell Signaling